Cullinan Therapeutics Q1 net loss $49.7M, cash $393.3M; zipalertinib NDA accepted with PDUFA Feb 2027

Cullinan Therapeutics, Inc.

Net loss of $49.7M for Q1 2026 vs $48.5M in Q1 2025; R&D expense $42.1M, G&A $11.6M.
Cash and investments $393.3M as of March 31, 2026; runway into 2029 under current plan.
FDA accepted NDA for zipalertinib in EGFR ex20ins NSCLC; PDUFA target date February 27, 2027.
Initial CLN-978 SLE and RA data to be presented at EULAR June 6, 2026; multi-dose RA data due Q3 2026.
Velinotamig initial SLE data expected Q4 2026; CLN-049 RP2D and AML update planned by Q4 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $49.7 million for the first quarter of 2026.

Period: first quarter ended March 31, 2026
Net income: Net loss was $49.7 million for the first quarter of 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.